Yahoo Finance

Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18, a Potential Game-Changing saRNA Therapeutic for Duchenne Muscular Dystrophy

NANTONG, China, Dec. 12, 2025 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in ...
Yahoo Finance

Ractigen Therapeutics Announces China NMPA IND Approval for Phase II Clinical Trial of saRNA Therapy RAG-01 in Non-Muscle Invasive Bladder Cancer

NANTONG, China, March 19, 2026 /PRNewswire/ -- Ractigen Therapeutics, a pioneering clinical-stage biotechnology company developing innovative small activating RNA (saRNA) therapeutics, today announced ...
manilatimes

Ractigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy

NANTONG, China, July 31, 2026 /PRNewswire/ -- Ractigen Therapeutics, a pioneer and global leader in small activating RNA (saRNA) therapeutics, today announced that the U.S. Food and Drug ...
MarketWatch

Ractigen Therapeutics Announces China NMPA IND Approval for Phase II Clinical Trial of saRNA Therapy RAG-01 in Non-Muscle Invasive Bladder Cancer

The MarketWatch News Department was not involved in the creation of this content. NANTONG, China, March 19, 2026 /PRNewswire/ -- Ractigen Therapeutics, a pioneering clinical-stage biotechnology ...